Clinical trials: Embryonal Neoplasm
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumors
Investigator Initiated Phase 1 Study of TBI-1301
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
- Trial name
- NCT02366546
- Testing
- TBI-1301, Cyclophosphamide, Fludarabine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Mie University
Glioblastoma Multiforme
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how…
- Trial name
- NCT01209442
- Testing
- Bevacizumab, Temozolomide, RT (Radiation Therapy)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Glioblastoma Multiform (Grade IV Astrocytoma)
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective…
- Trial name
- DESSTINI_A (NCT01833273)
- Testing
- PolyMVA
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stony Brook University
Melanoma
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
The purpose of this study is to describe real-world safety outcomes in children with melanoma who are treated with nivolumab alone or nivolumab in combination with ipilimumab for unresectable or metastatic melanoma, or treated…
- Trial name
- NCT06163170
- Testing
- Nivolumab +/- ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
- Trial name
- NCT00961090
- Testing
- Aminolevulinic Acid
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Matthew R Quigley
High Grade Gliomas, Brain Tumors
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Background: Radiation therapy with temozolomide (an anti-cancer drug) is standard therapy for treating brain tumors called glioblastomas.
- Trial name
- NCT00302159
- Testing
- adjuvant therapy, Temozolomide, Valproic Acid
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
BRAFV600E Melanoma Patients
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a…
- Trial name
- NCT01721603
- Testing
- Dabrafenib, Gamma Knife Radiosurgery, Trametinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Astrocytoma, Grade IV
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Glioblastomas (GBM) are the most common type of primary brain tumors with an annual incidence of approximately 500 patients in the Netherlands.
- Trial name
- NCT02432417
- Testing
- Chloroquine
- Sponsor
- Maastricht Radiation Oncology
Melanoma
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
This is open label, single arm study for pts with stage IIIB-IV melanoma, accordingly with AJCC staging criteria (8th ed.), with potentially resectable disease.
- Trial name
- NCT06566391
- Testing
- Ipilimumab
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
This phase Ib trial tests the safety, side effects, and best dose of STI-3031 given directly into the into the lymph nodes or the lymph vessels (intra-lymphatic) using the Sofusa DoseConnect device in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
- Trial name
- NCT05393713
- Testing
- Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Hepatic Sarcoma
Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered
Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age.
- Trial name
- SARCOM (NCT05640960)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Glycolytic Index
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors.
- Conditions
- Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
- Trial name
- NCT06059690
- Testing
- pH Measurement of in vivo tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Low-grade Glioma
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
The DAY101-EAP is a multicenter, open-label, expanded access treatment protocol designed to provide access to tovorafenib (DAY101) for eligible patients.
- Trial name
- NCT05760586
- Testing
- Tovorafenib
- Sponsor
- Day One Biopharmaceuticals, Inc.
Melanoma
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer.
- Trial name
- NCT01078961
- Testing
- bortezomib, sorafenib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Melanoma (Skin Cancer)
Investigation of the Performance of the Medical Device Dermalyser in Determining Melanoma Thickness Based on Dermoscopy Images
In Sweden, approximately 9,000 Swedes are affected by melanoma annually, and each year, 500 individuals die from metastatic melanoma. The prognosis for melanoma primarily depends on the thickness of the tumor at diagnosis.
- Trial name
- AI-DSII (NCT06788665)
- Testing
- Medical Device Dermalyser
- Where
- Sweden
- Volunteers
- 900 people
- Sponsor
- Vastra Gotaland Region
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002944
- Testing
- carboplatin, lomustine, procarbazine hydrochloride
- Where
- 204 sites in United States, Australia and 4 more
- Volunteers
- 428 people
- Sponsor
- Children's Oncology Group
Glioblastoma, High-Grade Gliomas
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Gliomas, Grade III Astrocytoma, Grade III Glioma
- Trial name
- NCT06975332
- Testing
- Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.